NDLI: Abnormalities in Glucose Regulation During Antipsychotic Treatment of Schizophrenia

Content Provider	JAMA Network
Author	Newcomer, John W. Haupt, Dan W. Fucetola, Robert Melson, Angela K. Schweiger, Julie A. Cooper, Benjamin P. Selke, Gregg
Copyright Year	2002
Abstract	Background: Hyperglycemia and type 2 diabetes mellitus are more common in schizophrenia than in the general population. Glucoregulatory abnormalities have also been associated with the use of antipsychotic medications themselves. While antipsychotics may increase adiposity, which can decrease insulin sensitivity, disease- and medication-related differences in glucose regulation might also occur independent of differences in adiposity. Methods: Modified oral glucose tolerance tests were performed in schizophrenic patients (n = 48) receiving clozapine, olanzapine, risperidone, or typical antipsychotics, and untreated healthy control subjects (n = 31), excluding subjects with diabetes and matching groups for adiposity and age. Plasma was sampled at 0 (fasting), 15, 45, and 75 minutes after glucose load. Results: Significant time × treatment group interactions were detected for plasma glucose ( F12,222= 4.89, P<.001) and insulin ( F12,171= 2.10, P= .02) levels, with significant effects of treatment group on plasma glucose level at all time points. Olanzapine-treated patients had significant (1.0-1.5 SDs) glucose elevations at all time points, in comparison with patients receiving typical antipsychotics as well as untreated healthy control subjects. Clozapine-treated patients had significant (1.0-1.5 SDs) glucose elevations at fasting and 75 minutes after load, again in comparison with patients receiving typical antipsychotics and untreated control subjects. Risperidone-treated patients had elevations in fasting and postload glucose levels, but only in comparison with untreated healthy control subjects. No differences in mean plasma glucose level were detected when comparing risperidone-treated vs typical antipsychotic–treated patients and when comparing typical antipsychotic–treated patients vs untreated control subjects. Conclusion: Antipsychotic treatment of nondiabetic patients with schizophrenia can be associated with adverse effects on glucose regulation, which can vary in severity independent of adiposity and potentially increase long-term cardiovascular risk.
Ending Page	345
Starting Page	337
Page Count	9
File Format	PDF HTM / HTML
ISSN	0003990X
DOI	10.1001/archpsyc.59.4.337
Issue Number	4
Journal	Archives of General Psychiatry
Volume Number	59
Language	English
Publisher	American Medical Association
Publisher Date	2002-04-01
Access Restriction	Open
Subject Keyword	glucose antipsychotic agents clozapine risperidone schizophrenia insulin plasma glucose obesity first-generation antipsychotics hyperglycemia fasting type 2 diabetes mellitus olanzapine oral glucose tolerance test adverse effects plasma
Content Type	Text
Resource Type	Article
Subject	1200/1201 Psychiatry and Mental Health

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Glucose Metabolism in Patients With Schizophrenia Treated With Atypical Antipsychotic Agents: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis

Impaired Glucose Homeostasis in First-Episode Schizophrenia: A Systematic Review and Meta-analysis

A Meta-analysis of the Efficacy of Second-Generation Antipsychotics

An Assessment of the Independent Effects of Olanzapine and Risperidone Exposure on the Risk of Hyperlipidemia in Schizophrenic Patients

Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial

Clozapine Use in Patients With Schizophrenia and the Risk of Diabetes, Hyperlipidemia, and Hypertension: A Claims-Based Approach

Diabetes and atypical antipsychotics

Childhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison

Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?

Abnormalities in Glucose Regulation During Antipsychotic Treatment of Schizophrenia

Similar Documents

Glucose Metabolism in Patients With Schizophrenia Treated With Atypical Antipsychotic Agents: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis

Impaired Glucose Homeostasis in First-Episode Schizophrenia: A Systematic Review and Meta-analysis

A Meta-analysis of the Efficacy of Second-Generation Antipsychotics

An Assessment of the Independent Effects of Olanzapine and Risperidone Exposure on the Risk of Hyperlipidemia in Schizophrenic Patients

Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial

Clozapine Use in Patients With Schizophrenia and the Risk of Diabetes, Hyperlipidemia, and Hypertension: A Claims-Based Approach

Diabetes and atypical antipsychotics

Childhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison

Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?

Abnormalities in Glucose Regulation During Antipsychotic Treatment of Schizophrenia